Dupilumab ELISA Kit

Catalog No.

KDD62601

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human CD124 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Dupilumab in the sample competitively binds to the pre-coated protein with biotin-labeled Dupilumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Dupilumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Dupilumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.13 - 5,000 ng/mL

Sensitivity

48.20 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	2227.27	541.12	143.98	2228.63	542.01	128.14
Standard deviation	150.28	43.08	18.33	204.99	27.46	11.34
CV (%)	6.75	7.96	12.73	9.20	5.07	8.85

Recovery

90-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.

Alternative Names

CD124, REGN668, SAR231893, CAS: 1190264-60-8

Background

Dupilumab is a human immunoglobulin G4 (IgG4) antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%. A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%.

The Efficacy of Dupilumab in Pemphigus Vulgaris., PMID:40514796

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register., PMID:40513967

Recalcitrant Grover's disease treated with dupilumab: two long-term cases and review of the literature., PMID:40509692

Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review., PMID:40507644

Dupilumab-Induced Remission in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: A 24-Month Study., PMID:40507416

Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 Inhibitors., PMID:40507326

Dupilumab in an adolescent with eosinophilic esophagitis and eosinophilic duodenitis, a valuable treatment option., PMID:40504588

Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study., PMID:40503236

STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment., PMID:40502541

Paradoxical Effects of Dupilumab in ABPA: Resolution of Mucus Plugging but Induction of Eosinophilic Pneumonia., PMID:40499647

Auditory and Ocular Manifestations in Pediatric Vitiligo., PMID:40498511

Dupilumab and Blood Eosinophilia: A Disease-Specific Phenomenon?, PMID:40492692

[Application and research progress of anti-IL-4α monoclonal antibody dupilumab in the treatment of type 2 asthma]., PMID:40491151

Eosinophilic esophagitis in children: new kids on the block., PMID:40490426

Aspirin-Exacerbated Respiratory Disease in the era of biologics., PMID:40490219

Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database., PMID:40490170

Wells syndrome: emerging triggers and treatments- an updated systematic review., PMID:40488888

Effectiveness of Dupilumab Treatment in Patients With Type 2 Inflammation: A Real-Life Integrated Experience., PMID:40487737

Dupilumab-Induced Granuloma Annulare: A Challenging Adverse Effect of Atopic Dermatitis Treatment., PMID:40487493

Dupilumab Improves Histopathologic Features in Patients With Eosinophilic Esophagitis: LIBERTY EoE TREET Study Results., PMID:40487268

Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions., PMID:40486460

Cost-utility analysis of sequential therapies for pediatric-onset eosinophilic esophagitis., PMID:40485534

A nationwide experience of biological treatments in children with eosinophilic esophagitis., PMID:40483369

Reply to "Considerations for enhancing dupilumab research in hypereosinophilic syndromes"., PMID:40483017

Considerations for enhancing dupilumab research in hypereosinophilic syndromes., PMID:40483016

Clinical and complete remission in patients with severe asthma with 24-month dupilumab treatment., PMID:40482373

Long-term effectiveness and safety of dupilumab in severe asthma: a 5-year real-world multicenter study., PMID:40480546

Real-World Efficacy and Safety of Dupilumab Retreatment in Adults With Relapsed Atopic Dermatitis: A Retrospective Study From China., PMID:40474541

Efficacy and glucocorticoid sparing of dupilumab in IgG4-related disease: a case series and literature review., PMID:40470558

Angiolymphoid hyperplasia with eosinophilia treated with dupilumab in a biologic-naïve patient., PMID:40466455

Effect of dupilumab for the therapy of atopic dermatitis and the effect on serum TARC, HBD2 and SEA-IgE levels and peripheral blood T helper cell subtypes., PMID:40462855

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study., PMID:40459712

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study., PMID:40459711

Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions., PMID:40458676

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis., PMID:40457140

An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis., PMID:40456762

[Not Available]., PMID:40456219

[Not Available]., PMID:40456218

Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health-Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis., PMID:40452334

Infectious complications of atopic dermatitis, an update., PMID:40447099

[Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies., PMID:40446917

Impacto de dupilumab en la calidad de vida, ansiedad y depresión en pacientes adultos afectados por dermatitis atópica moderada-severa y sus convivientes: un estudio prospectivo., PMID:40446914

[[Translated article]]Treatment of Bullous Pemphigoid with Dupilumab: Retrospective, Single-Center Study in a Spanish Tertiary Referral Center., PMID:40446909

Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?, PMID:40442566

Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of three clinical trials., PMID:40441387

Egg Oral Immunotherapy With Dupilumab Premedication in an Adult Patient., PMID:40440105

Contemporary Concise Review 2024: Chronic Obstructive Pulmonary Disease., PMID:40437348

Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch., PMID:40436117

Joint Pain and Inflammatory Arthropathy after Dupilumab Use in Atopic Dermatitis: A Systematic Review and Meta-Analysis., PMID:40435582

Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma., PMID:40432729

Document Download

Dupilumab ELISA Kit.pdf